A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax

被引：1

作者：

Sharpe, Chia ^{[1
]}

Elgamal, Sara ^{[1
]}

Fobare, Sydney ^{[2
]}

Furby, Casie ^{[1
]}

Long, Marissa ^{[1
]}

Bryant, Kinsey ^{[1
]}

Cheney, Carolyn ^{[1
]}

Lerma, James R. ^{[1
]}

Johnstone, Megan E. ^{[1
]}

Orry, Andrew ^{[3
]}

Lam, Polo Chun-Hung ^{[3
]}

Abagyan, Ruben ^{[3
]}

Kysil, Volodymyr ^{[4
]}

Gukasyan, Hovhannes ^{[4
]}

Mitkin, Oleg ^{[4
]}

Karapetian, Ruben ^{[4
]}

Ryakhovskiy, Alexey ^{[4
]}

Bulanova, Elena ^{[4
]}

Parchinsky, Vladislav ^{[4
]}

Ivachtchenko, Alexandre ^{[4
]}

Dokukina, Kate ^{[5
]}

Pushechnikov, Alexei ^{[4
]}

Savchuk, Nikolay ^{[5
]}

Dukes, Iain ^{[5
]}

Burd, Amy ^{[5
]}

Hertlein, Erin K. ^{[1
]}

Byrd, John C. ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA

[2] Ohio State Univ, Med Scientist Training Program, Columbus, OH USA

[3] MolSoft LLC, San Diego, CA USA

[4] ChemDiv Inc, San Diego, CA USA

[5] Eilean Therapeut, Philadelphia, PA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189266

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
Borthakur, Gautam M.
Kadia, Tapan M.
Al Azzawi, Hind
Zheleva, Daniella
Blake, David
Chiao, Judy H.
BLOOD, 2019, 134
[22] Evaluating the effects of Bcl2 inhibitor, venetoclax, on cellular growth and clustering in triple-negative breast cancer cells
Ruiz, Alexis Jordan
Park, Nicolas
Abdulkareem, Noor
Trivedi, Meghna
CANCER RESEARCH, 2023, 83 (07)
[23] Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
Blombery, Piers
Birkinshaw, Richard W.
Nguyen, Tamia
Gong, Jia-nan
Thompson, Ella R.
Xu, Zhen
Westerman, David A.
Czabotar, Peter E.
Dickinson, Michael
Huang, David C. S.
Seymour, John F.
Roberts, Andrew W.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (06) : E188 - E191
[24] Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax
Blombery, Piers
Thompson, Ella
Tamia Nguyen
Chen, Xiangting
McBean, Michelle
Birkinshaw, Richard W.
Czabotar, Peter E.
Thijssen, Rachel
Anderson, Mary Ann
Seymour, John F.
Westerman, David Alan
Huang, David C. S.
Roberts, Andrew W.
BLOOD, 2019, 134
[25] The novel eIF4A inhibitor potently synergizes with BCL2 inhibitor in high grade B-cell lymphoma with MYC and BCL2 rearrangements through regulating UPR
Seol, So-Young
Park, Chung Hyun
Kim, Soo Jeong
Chung, Haerim
Cho, Hyunsoo
Kim, Jin Seok
Kim, Yu Ri
CANCER RESEARCH, 2024, 84 (06)
[26] Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers
Ahmed Hamed Salem
Beibei Hu
Kevin J. Freise
Suresh K. Agarwal
Dilraj S. Sidhu
Shekman L. Wong
Clinical Drug Investigation, 2017, 37 : 303 - 309
[27] Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers
Salem, Ahmed Hamed
Hu, Beibei
Freise, Kevin J.
Agarwal, Suresh K.
Sidhu, Dilraj S.
Wong, Shekman L.
CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 303 - 309
[28] Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer
Becker, Jeffrey H.
Metropulos, Anastasia E.
Spaulding, Christina
Marinelarena, Alejandra M.
Shields, Mario A.
Principe, Daniel R.
Pham, Thao D.
Munshi, Hidayatullah G.
CANCER RESEARCH, 2024, 84 (21) : 3629 - 3639
[29] A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer
Lok, Sheau W.
Whittle, James R.
Vaillant, Francois
Teh, Charis E.
Lo, Louisa L.
Policheni, Antonia N.
Bergin, Alice R. T.
Desai, Jayesh
Ftouni, Sarah
Gandolfo, Luke C.
Liew, Danny
Liu, He K.
Mann, G. Bruce
Moodie, Kate
Murugasu, Anand
Pal, Bhupinder
Roberts, Andrew W.
Rosenthal, Mark A.
Shackleton, Kylie
Silva, Maria Joao
Siow, Zhen R.
Smyth, Gordon K.
Taylor, Leanne
Travers, Avraham
Yeo, Belinda
Yeung, Miriam M.
Bujak, Andjelija Zivanovic
Dawson, Sarah-Jane
Gray, Daniel H. D.
Visvader, Jane E.
Lindeman, Geoffrey J.
CANCER DISCOVERY, 2019, 9 (03) : 354 - 369
[30] STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX
Karjalainen, R.
Popa, M.
Liu, M.
Javarappa, K. K.
Kontro, M.
Parsons, A.
Porkka, K.
Wennerberg, K.
McCormack, E.
Gjertsen, B. T.
Heckman, C. A.
HAEMATOLOGICA, 2017, 102 : 39 - 39

← 1 2 3 4 5 →